Wilmington, Delaware, Transparency Market Research Inc.:, Dec. 02, 2024 (GLOBE NEWSWIRE) — The global oligonucleotides market (mercado de oligonucleótidos) is poised for significant growth, projected to expand at a robust CAGR of 11.9% from 2024 to 2034. Valued at US$ 3.7 billion in 2023, the market is expected to reach over US$ 13.1 billion by 2034. The increasing adoption of oligonucleotides in molecular biology and gene therapy, coupled with advancements in biotechnology, is propelling the demand for these versatile molecules across various applications.
The growing number of FDA-approved oligonucleotide drugs, particularly for the treatment of genetic disorders, cancers, and viral infections, is a key factor driving market expansion.
Oligonucleotides, short DNA or RNA molecules, are increasingly used in gene therapy, diagnostics, and molecular biology due to their ability to hybridize with specific nucleotide sequences. This property enhances their application in technologies like PCR, DNA microarrays, and RNA interference (RNAi) therapies. As precision medicine and targeted treatments continue to grow, the role of oligonucleotides in both research and clinical settings becomes more crucial.
Request a PDF Sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86409
Competitive Landscape and Key Market Players
The global oligonucleotides market is highly fragmented, with the presence of several established and emerging players. Key players in the market include Agilent Technologies, Ajinomoto Bio-Pharma Services, CordenPharma, Creative Biolabs, Ella Biotech, Eurofins Genomics, Integrated DNA Technologies, Thermo Fisher Scientific, Merck, Microsynth, Ribo Biotechnology, and STA Pharmaceutical/Wuxi STA.
These companies are increasingly focusing on expanding their product offerings and developing innovative oligonucleotide-based therapies to address the growing demand in molecular biology, drug development, and personalized medicine.
Recent Industry Developments
- Agilent Technologies, a prominent player in the life sciences sector, recently launched a new range of oligonucleotide synthesis products aimed at improving the efficiency and accuracy of RNA interference applications. This expansion of their product portfolio is expected to contribute significantly to the growth of the oligonucleotide market.
- Thermo Fisher Scientific has strengthened its position in the market by acquiring Phadia, a leading provider of diagnostic solutions. This acquisition enables Thermo Fisher to enhance its capabilities in genetic testing, leveraging oligonucleotide-based diagnostic techniques for personalized medicine.
Ask for a Custom Research Report Sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86409
Key Drivers of Oligonucleotides Market Growth
- Increasing Demand for Gene Therapy and Personalized Medicine
Oligonucleotides are at the forefront of the rapidly expanding gene therapy market. Their ability to modulate gene expression at the molecular level has made them crucial in developing personalized medicine, especially for rare genetic disorders and cancers. This demand for precise, targeted therapies is fueling the market for oligonucleotides. - Technological Advancements in Oligonucleotide Synthesis
The continuous innovation in synthesis technologies, particularly in solid-phase chemical techniques, has improved the production efficiency and customization of oligonucleotides. This allows for more affordable, tailored solutions that meet specific client requirements, further broadening their application in molecular biology, drug development, and diagnostics. - Expanding Applications in Diagnostics
Oligonucleotides are increasingly being employed in diagnostic applications, including PCR assays, DNA sequencing, and genetic screening. Their ability to identify specific genetic sequences with high precision makes them indispensable tools in clinical diagnostics, contributing to the growth of the market. - Growing Number of FDA-Approved Oligonucleotide Drugs
The increasing approval of oligonucleotide-based drugs by the FDA is enhancing the credibility and potential of oligonucleotides in treating complex diseases. Their role in treating genetic disorders, cancers, and viral infections is opening new opportunities for drug developers, with a growing number of biopharmaceutical companies entering the market.
Market Segmentation
The oligonucleotides market is segmented based on type, application, end-user, and region.
By Type:
- Antisense Oligonucleotides
- DNA Oligos
- siRNA
- Others (CpG Oligonucleotides)
By Application:
- Molecular Biology
- Gene Therapy
- Drug Development
- Diagnostics
- Others (Nanotechnology, Research Studies, etc.)
By End-User:
- Hospitals
- Pharma & Biopharma Companies
- Diagnostic Laboratories
- Biotechnology Companies
- CROs and CMOs
- Others (Academic Research Institutes, etc.)
Regions Covered:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Outlook for the Future
As the demand for personalized medicine continues to rise, oligonucleotides will play an increasingly pivotal role in the development of novel therapies and diagnostics. With ongoing advancements in synthesis technologies, regulatory approvals, and growing applications in biotechnology, the market is well-positioned for substantial growth over the next decade.
Additionally, the ongoing collaborations between pharmaceutical companies and biotechnology firms are expected to accelerate the development of innovative oligonucleotide-based treatments, further expanding their market potential.
Buy this Premium Research Report Now – https://www.transparencymarketresearch.com/checkout.php?rep_id=86409<ype=S
The oligonucleotides market is set to remain at the forefront of the biopharmaceutical and molecular biology industries, with new opportunities for growth and development on the horizon.
Explore Trending Research Reports in the Healthcare Industry:
- Low Endotoxin Gelatin Market (Mercado de Gelatina Baja en Endotoxinas): Expected to grow at a CAGR of 6.4% from 2024 to 2034 and reach US$ 1.7 Bn by the end of 2034
- Nucleic Acid Aptamers Market (核酸アプタマー市場): Projected to advance at a CAGR of 17.2% from 2024 to 2034 and reach more than US$ 1.2 Bn by the end of 2034
Top of Form
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter| Blog | YouTube
